Mefloquine (Mefloquine Hydrochloride)

Mefloquine interferes with the parasite’s hemoglobin digestion and destabilizes its cell membrane. By binding to heme, it prevents hemozoin formation, leading to toxic free heme buildup, oxidative stress, and ultimately death of the malaria parasite.

The specific dose and regimen of mefloquine are determined by the prescribing clinician based on the indication, patient weight, age, and local resistance patterns. Patients should follow the exact instructions provided by their healthcare professional.

Safety data for mefloquine in pregnancy and lactation are limited. Clinicians must weigh potential benefits against risks and consider alternative therapies when possible. Pregnant or breastfeeding individuals should discuss use with their healthcare provider.

To request mefloquine, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Mefloquine is particularly effective against chloroquine‑resistant Plasmodium falciparum, whereas drugs like chloroquine are less active in resistant regions. Compared with artemisinin‑based combination therapies, mefloquine offers a longer half‑life, allowing less frequent dosing for prophylaxis, but it may have a higher incidence of neuropsychiatric side effects.

Mefloquine should be stored at ambient temperature, below 25 °C, in its original container, protected from moisture and direct sunlight. Keeping the product in a dry, cool place helps maintain its stability and potency.

Mefloquine is taken orally, usually with a full glass of water. For prophylaxis, it is started before travel, taken weekly during exposure, and continued for a short period after leaving the endemic area. For treatment, the prescribed regimen is followed as directed by the prescriber.

Serious risks include neuropsychiatric events such as severe anxiety, depression, psychosis, and rare seizures, as well as cardiac arrhythmias due to QT prolongation and severe allergic reactions. Patients should seek immediate medical attention if they experience any of these symptoms.

Mefloquine is contraindicated in individuals with known hypersensitivity to quinoline antimalarials, a history of severe psychiatric disorders, uncontrolled epilepsy, or significant cardiac disease that predisposes to QT prolongation. It should also be used with caution in patients with hepatic impairment.